A Phase 2 interventional study of Memantine Hydrochloride (HCl) in Autism Spectrum Disorder (ASD), Autism and Autistic Disorder, sponsored by Forest Laboratories. Terminated at 106 sites in 16 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2015-02-16.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 8th largest by enrollment of the 658 interventional ones that give a count, is one of 26 that started in 2012, is one of 101 in phase 2, and was the 89th registered.
1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.
Browse Autism Spectrum Disorder studies →165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 1 more country
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 26 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 747 is above the median of 51 across 1,371 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 522 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AbbVie has 6 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
67 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 67 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
This clinical study was a 48-week, multicenter, multinational, open-label extension study in pediatric outpatients with autism, Asperger's Disorder, or PDD-NOS conducted at 106 study centers. Patients were eligible for this long-term extension study if they had:
The weight-based dose limits in this study were as follows:
Group A: ≥ 60 kg; maximum 15 mg/day Group B: 40-59 kg; maximum 9 mg/day Group C: 20-39 kg; maximum 6 mg/day Group D: \< 20 kg; maximum 3 mg/day
The decision to close the study early was based on data from 2 double-blind placebo-controlled studies (MEM-MD-57A and MEM-MD-68) that failed to demonstrate a statistically significant difference between memantine and placebo in the primary efficacy parameter based on Social Responsiveness Scale (SRS) total raw score.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing. Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage.
Drug: Memantine Hydrochloride (HCl)
During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily. During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily.
Also known as: Namenda
Patients With Any Treatment-emergent Adverse Event
Number of patients who experienced 1 or more Treatment Emergent Adverse Event
Time frame: Visit 1 (Week 0) up to 30 days after Visit 8 (up to Week 48) or Final Visit
Patient recruitment occurred over an eleven month period, from October of 2012 to September of 2013, at 106 study sites, located in the United States and 15 other countries.
| Milestone | Memantine |
|---|---|
| Started | 747 |
| Completed | 81 |
| Not completed | 666 |
| Withdrew: Study terminated by sponsor | 582 |
| Withdrew: Withdrawal by subject | 35 |
| Withdrew: Lost to follow-up | 19 |
| Withdrew: Adverse event | 17 |
| Withdrew: Lack of efficacy | 9 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Inclusion/exclusion not meet | 1 |
| Withdrew: Other reason | 1 |
Number of patients who experienced 1 or more Treatment Emergent Adverse Event
| participants | Memantine |
|---|---|
| Patients With Any Treatment-emergent Adverse Event | 424 |
Collected over Adverse Event data was collected from October 2012 to February 2014 at 106 sites in the US and 15 other countries.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine | — | 8/747 (1.1%) | 150/747 (20.1%) |
| Event | Memantine |
|---|---|
| Abdominal painGastrointestinal disorders | 1/747 |
| Abdominal pain lowerGastrointestinal disorders | 1/747 |
| Abnormal behaviourNervous system disorders | 1/747 |
| AppendicitisInfections and infestations | 1/747 |
| DehydrationInvestigations | 1/747 |
| DysphoriaNervous system disorders | 1/747 |
| Foreign bodyInjury, poisoning and procedural complications | 1/747 |
| Homicidal ideationNervous system disorders | 1/747 |
| Rectal prolapseInjury, poisoning and procedural complications | 1/747 |
| Suicidal ideationNervous system disorders | 1/747 |
| Event | Memantine |
|---|---|
| NasopharyngitisInfections and infestations | 55/747 |
| VomitingGastrointestinal disorders | 51/747 |
| PyrexiaGeneral disorders | 47/747 |
| HeadacheNervous system disorders | 41/747 |
Demographic summaries were provided based on the 747 patients who received at least 1 dose of investigational product in the extension study (Safety Population).
| Age, Continuous(years) | Memantine |
|---|---|
| Mean | 9.0 ± 1.9 |
| Sex: Female, Male(Participants) | Memantine |
|---|---|
| Female | 120 |
| Male | 627 |
| Race/Ethnicity, Customized(participants) | Memantine |
|---|---|
| White | 636 |
| Black or African American | 42 |
| Asian | 44 |
| American Indian or Alaska Native | 2 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Other Race | 20 |
| Race/Ethnicity, Customized(participants) | Memantine |
|---|---|
| Hispanic or Latino | 88 |
| Not Hispanic or Latino | 659 |
| Region of Enrollment(participants) | Memantine |
|---|---|
| United States | 586 |
| Belgium | 4 |
| Canada | 1 |
| Colombia | 8 |
| Estonia | 5 |
| France | 9 |
| Hungary | 14 |
| Iceland | 5 |
| Italy | 6 |
| Korea, Republic of | 22 |
| New Zealand | 1 |
| Poland | 36 |
| Serbia | 21 |
| South Africa | 1 |
| Spain | 14 |
| Ukraine | 14 |
Showing the first 100 of 106 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine